The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business Research Company’s liver diseases therapeutics market report forecasts the liver diseases therapeutics market size to grow to $17.41 Billion by 2027, with a CAGR (compound annual growth rate) of more than 7%.

Learn More On The Liver Diseases Therapeutics Market Report 2023 – https://www.thebusinessresearchcompany.com/report/liver-diseases-therapeutics-global-market-report

Liver Diseases Therapeutics Market Size Forecast
The global liver diseases therapeutics market is expected to grow from $12.10 billion in 2022 to $13.09 billion in 2023 at a compound annual growth rate (CAGR) of 8.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The liver diseases therapeutics market size is expected to grow to $17.41 billion in 2027 at a CAGR of 7.4%.

North America held the largest liver diseases therapeutics market share, and Asia-Pacific was the fastest-growing region in 2022.

Key Liver Diseases Therapeutics Market Driver ­– Rise In The Prevalence Of Liver Diseases
For instance, in 2020, according to The Centers for Disease Control and Prevention (CDC), the number of deaths from alcoholic liver disease was 29,505 in the United States. Therefore, the rising prevalence of liver diseases drives the growth of the liver disease therapeutics market.

Request for A Sample Of The Global Liver Diseases Therapeutics Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=7969&type=smp

Key Liver Diseases Therapeutics Market Trend – Strategic Partnerships
Major companies operating in the liver diseases therapeutics market are undergoing collaborations to strengthen their position in the liver diseases therapeutics market. For instance, in January 2022, Aligos Therapeutics Inc., a US-based clinical-stage biopharmaceutical company, collaborated with Merck & Co, a US-based company operating in liver disease therapeutics. This collaboration is to discover and develop oligonucleotide therapies for non-alcoholic steatohepatitis. Further, in January 2021, Novartis, a Switzerland-based company operating in liver disease therapeutics collaborated with Alnylam, a US-based biopharmaceutical company. This collaboration aims to develop liver-targeted therapy as a potential alternative to transplantation for patients experiencing liver failure.

Liver Diseases Therapeutics Market Segment
1) By Disease Type: Hepatitis, Non-Alcoholic Fatty Liver Disease, Alcohol-Induced, Liver Cancer
2) By Treatment: Antiviral, Vaccines, Chemotherapy, Immunosuppressive Agents, Corticosteroids
3) By End User: Hospitals, Ambulatory Surgery Centers, Other End Users

Liver Diseases Therapeutics Market Major Players and Strategies
Major players in the liver diseases therapeutics market are Astellas Pharma Inc., Bristol-Myers Squibb Company, F Hoffmann-La Roche AG, Merck & Co Inc., Novartis AG, GlaxoSmithKline Plc, Abbott Laboratories Inc., Pfizer Inc., Sanofi SA, Johnson & Johnson Services Inc., Bayer AG, Abbvie Inc., The Takeda Pharmaceutical Company Limited, Valeant Pharmaceuticals, Watson Pharmaceuticals Inc., and AstraZeneca plc.

In September 2022, GENFIT, a France-based biopharmaceutical company, acquired Versantis for an undisclosed amount. This acquisition of Versantis’ expertise with GENFIT’s know-how in conducting complex development programs in liver diseases, strengthens and accelerates research and development and significantly expands GENFIT’s pipeline. Versantis is a Switzerland-based company operating in liver disease therapeutics.

The Liver Diseases Therapeutics Global Market Report 2023 covers regional data on liver diseases therapeutics market size, liver diseases therapeutics market trends and drivers, opportunities, strategies, and liver diseases therapeutics market competitor analysis. The countries covered in the liver diseases therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Liver disease therapeutics refers to the treatment of numerous types of liver illnesses, diseases brought on by viruses, including hepatitis A, B, and C. These diseases are mainly caused by consuming more alcohol.

View More Reports Related To The Liver Diseases Therapeutics Market –
Digital Therapeutics Global Market Report 2023
Transplant Diagnostics Global Market Report 2023
Neurodegenerative Disorder Therapeutics Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: